IL1B and colitis: Zhao et al. [52] reported that 100 mg/kg LBP-derived arabinogalactan decreases intestinal IL-1β and TNF-α expression by 31% and increases ZO-1 and occludin mRNA levels by 39% and 17%, respectively, in colitis mice.